AU2023253718A1 - Capsid variants and methods of using the same - Google Patents

Capsid variants and methods of using the same Download PDF

Info

Publication number
AU2023253718A1
AU2023253718A1 AU2023253718A AU2023253718A AU2023253718A1 AU 2023253718 A1 AU2023253718 A1 AU 2023253718A1 AU 2023253718 A AU2023253718 A AU 2023253718A AU 2023253718 A AU2023253718 A AU 2023253718A AU 2023253718 A1 AU2023253718 A1 AU 2023253718A1
Authority
AU
Australia
Prior art keywords
seq
polypeptide
compared
capsid
mutation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023253718A
Other languages
English (en)
Inventor
Hanna LEVITIN
Heikki Turunen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dyno Therapeutics Inc
Original Assignee
Dyno Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyno Therapeutics Inc filed Critical Dyno Therapeutics Inc
Publication of AU2023253718A1 publication Critical patent/AU2023253718A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2023253718A 2022-04-15 2023-04-14 Capsid variants and methods of using the same Pending AU2023253718A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263331543P 2022-04-15 2022-04-15
US63/331,543 2022-04-15
US202363443262P 2023-02-03 2023-02-03
US63/443,262 2023-02-03
PCT/US2023/065815 WO2023201364A2 (en) 2022-04-15 2023-04-14 Capsid variants and methods of using the same

Publications (1)

Publication Number Publication Date
AU2023253718A1 true AU2023253718A1 (en) 2024-11-28

Family

ID=88330421

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023253718A Pending AU2023253718A1 (en) 2022-04-15 2023-04-14 Capsid variants and methods of using the same

Country Status (10)

Country Link
US (1) US20250250305A1 (cg-RX-API-DMAC7.html)
EP (1) EP4508064A2 (cg-RX-API-DMAC7.html)
JP (1) JP2025512534A (cg-RX-API-DMAC7.html)
KR (1) KR20250011900A (cg-RX-API-DMAC7.html)
CN (1) CN119630688A (cg-RX-API-DMAC7.html)
AU (1) AU2023253718A1 (cg-RX-API-DMAC7.html)
CA (1) CA3255976A1 (cg-RX-API-DMAC7.html)
IL (1) IL316205A (cg-RX-API-DMAC7.html)
MX (1) MX2024012615A (cg-RX-API-DMAC7.html)
WO (1) WO2023201364A2 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120699111B (zh) * 2025-08-26 2025-12-30 朗信启昇(苏州)生物制药有限公司 增强型aav载体及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3265178T3 (fi) * 2015-03-02 2026-08-03 Adverum Biotechnologies Inc Koostumuksia ja menetelmiä polynukleotidien viemiseksi intravitreaalisesti retinaalisiin tappisoluihin
WO2017197355A2 (en) * 2016-05-13 2017-11-16 4D Molecular Therapeutics Inc. Adeno-associated virus variant capsids and methods of use thereof
MX2023001109A (es) * 2020-07-27 2023-04-24 Anjarium Biosciences Ag Composiciones de moleculas de adn, metodos para elaborar las mismas, y metodos de usos de las mismas.
KR20240045198A (ko) * 2021-06-03 2024-04-05 디노 테라퓨틱스, 인코포레이티드 캡시드 변이체 및 이의 사용 방법

Also Published As

Publication number Publication date
EP4508064A2 (en) 2025-02-19
IL316205A (en) 2024-12-01
KR20250011900A (ko) 2025-01-22
WO2023201364A2 (en) 2023-10-19
CN119630688A (zh) 2025-03-14
MX2024012615A (es) 2025-02-10
JP2025512534A (ja) 2025-04-17
WO2023201364A3 (en) 2023-11-16
CA3255976A1 (en) 2023-10-19
US20250250305A1 (en) 2025-08-07

Similar Documents

Publication Publication Date Title
US20240368228A1 (en) Capsid variants and methods of using the same
US20210162071A1 (en) Adeno-associated virus variant capsids and methods of use thereof
US20250352671A1 (en) Capsid variants and methods of using the same
CA3220810A1 (en) Capsid variants and methods of using the same
US20250250305A1 (en) Capsid variants and methods of using the same
US20260102516A1 (en) Capsid variants and methods of using the same
US20250353882A1 (en) Capsid variants and methods of using the same
CN117940446A (zh) 衣壳变体及其使用方法
US20250269055A1 (en) Capsid variants and methods of using the same
US20240287141A1 (en) Capsid variants and methods of using the same
US20240277869A1 (en) Capsid variants and methods of using the same
CN117979953A (zh) 衣壳变体及其使用方法
HK40092218A (en) Adeno-associated virus variant capsids and methods of use thereof
HK40091836A (en) Adeno-associated virus variant capsids and methods of use thereof